Clinical Trial Update: Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) [Phase 3]

View source ↗

Summary

Phase 3 trial of verubecestat (MK-8931) in prodromal Alzheimer's disease and amnestic MCI was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Amnestic Mild Cognitive Impairment
• Prodromal Alzheimer Disease

Drugs mentioned

• Verubecestat (MK-8931)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Amnestic Mild Cognitive Impairment, Alzheimer's Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-05-17